Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Soluble complement receptor 1: TCEL and SmithKline Beecham agreed to close the initial Phase I trial of sCR1 conducted by SmithKline in burn patients at risk of

The trial will be unblinded and data analyzed and used to provide initial safety and pharmacokinetic

Read the full 166 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers